ABSTRACT
The purpose of this review was to analyze the scientific literature on exocrine pancreatic insufficiency (EPI) in dogs and cats and our own research on porcine model to compare animal- and microbial-derived enzymes in the treatment of animals with this disease. Clinical signs of EPI occur when more than 85% of the pancreatic parenchyma is non-functional. EPI can be a consequence of various diseases. The insufficient activity or deficiency of pancreatic enzymes leads to impaired digestion and absorption, and consequently, to malnutrition. The primary treatment for enzyme insufficiency is pancreatic enzyme replacement therapy (PERT). PERT in animals with EPI is a lifetime therapy. Most commercially available products are of animal origin (processed pancreata obtained from a slaughter house) and contain lipases, alpha-amylase, and proteases. Enzymes of microbial and plant origin seem to be a promising alternative to animal-derived enzymes, but to date there are no registered preparations containing all enzymes simultaneously for use in clinical practice to treat EPI. Results from some previous studies have highlighted the "extra-digestive" functions of pancreatic enzymes, as well as the actions of pancreatic-like microbial enzymes. For example, trypsin activates protease-activated receptor and provokes maturation of enterocytes and enterostatin inhibits fat absorption. It has been postulated that intrapancreatic amylase is the main component of the acini-islet-acinar axis-the reflex which down regulates insulin release, while gut and blood amylase exhibit anti-incretin actions "per se." Additionally, high but still physiological blood amylase activity coincide with physiological glucose homeostasis and a lack of obesity.
Subject(s)
Cat Diseases , Dog Diseases , Enzyme Replacement Therapy , Exocrine Pancreatic Insufficiency , Animals , Exocrine Pancreatic Insufficiency/veterinary , Exocrine Pancreatic Insufficiency/drug therapy , Exocrine Pancreatic Insufficiency/enzymology , Dog Diseases/drug therapy , Dog Diseases/enzymology , Cat Diseases/drug therapy , Cat Diseases/enzymology , Dogs , Enzyme Replacement Therapy/veterinary , Cats , Swine , Pancreas/enzymology , Lipase/metabolismABSTRACT
Tumor-infiltrating lymphocyte (TIL) density plays an important role in anti-tumor immunity and is associated with patient outcome in various human and canine malignancies. As a first assessment of the immune landscape of the tumor microenvironment in canine renal cell carcinoma (RCC), we retrospectively analyzed clinical data and quantified CD3, FoxP3, and granzyme B immunostaining in formalin-fixed paraffin-embedded tumor samples from 16 dogs diagnosed with renal cell carcinoma treated with ureteronephrectomy. Cell density was low for all markers evaluated. Increased numbers of intratumoral FoxP3 labelled (+) cells, as well as decreased granzyme B+: FoxP3+ TIL ratio, were associated with poor patient outcomes. Our initial study of canine RCC reveals that these tumors are immunologically cold and Tregs may play an important role in immune evasion.
Subject(s)
CD3 Complex , Carcinoma, Renal Cell , Dog Diseases , Forkhead Transcription Factors , Granzymes , Kidney Neoplasms , Lymphocytes, Tumor-Infiltrating , Animals , Dogs , Carcinoma, Renal Cell/veterinary , Carcinoma, Renal Cell/immunology , Carcinoma, Renal Cell/enzymology , CD3 Complex/analysis , CD3 Complex/metabolism , Dog Diseases/immunology , Dog Diseases/enzymology , Forkhead Transcription Factors/analysis , Forkhead Transcription Factors/metabolism , Granzymes/metabolism , Granzymes/analysis , Immunohistochemistry/veterinary , Kidney Neoplasms/veterinary , Kidney Neoplasms/immunology , Kidney Neoplasms/enzymology , Lymphocytes, Tumor-Infiltrating/immunology , Retrospective StudiesABSTRACT
A number of inherited ataxias is known in humans, with more than 250 loci implicated, most of which are included in human ataxia screening panels. Anecdotally, cases of ataxia in the Norwegian elkhound black have been known for the last 40 years. Affected puppies from three litters were clinically and neurologically examined, and postmortem samples were collected for morphological studies, including ultrastructural analyses. The puppies displayed vestibulocerebellar neurological signs and had degenerative histopathological alterations in cerebellum and brain stem. Three affected dogs, each from different litters, as well as both parents and one healthy littermate from each litter, were whole genome sequenced. Through variant calling we discovered a disease-associated 1 bp deletion in HACE1 (CFA12), resulting in a frameshift at codon 333 and a premature stop codon at codon 366. The perfect association combined with the predicted significant molecular effect, strongly suggest that we have found the causative mutation for Norwegian elkhound black ataxia. We have identified a novel candidate gene for ataxia where dogs can serve as a spontaneous model for improved understanding of ataxia, also in human.
Subject(s)
Ataxia/genetics , Base Sequence , Dog Diseases/genetics , Models, Genetic , Sequence Deletion , Ubiquitin-Protein Ligases/genetics , Animals , Ataxia/enzymology , Ataxia/pathology , Dog Diseases/enzymology , Dog Diseases/pathology , Dogs , Male , Ubiquitin-Protein Ligases/metabolismABSTRACT
BACKGROUND: Hepatopathies are an important group of disorders in dogs where proper nutritional care is crucial. Supplementation with a hepatoprotectant like silybin can improve liver function and should not interfere with nutrient digestibility. The purpose of this study was to investigate the effect of both pure silybin and commercial hepatoprotectant on nutrients digestibility, liver function indices and health status in healthy dogs (EXP1). Moreover, the second experiment (EXP2) investigated the effect of commercial hepatoprotectant on liver function tests and liver-associated miRNAs concentration in dogs with idiopathic liver disorder. RESULTS: Nutrient digestibility was not affected by treatment in EXP1. Supplementation did alter the serum fatty acid profile, with no clinical relevance. The levels of liver markers such as ALT, AST and GGT significantly decreased. In EXP2, supplementation with commercial hepatoprotectant containing silybin improved liver function tests. A decrease was observed in liver serum markers such as ALT, AST and miR122 concentration. CONCLUSIONS: EXP1 confirmed that silybin (whether pure or as a commercial hepatoprotectant) does not interfere with digestion which subsequently exerts no detrimental effect on dogs' health and metabolism. In EXP2, dietary supplementation with commercial hepatoprotectant containing silybin resulted in a decreased activity of serum liver markers, accompanied by a decrease in the concentration of liver-specific miRNA molecules. Liver function indices were consequently improved. Silybin supplementation can thus serve as an effective therapeutical tool in dogs with hepatopathies.
Subject(s)
Dietary Supplements , Liver Diseases/diet therapy , Silybin/pharmacology , Animal Feed/analysis , Animals , Biomarkers/blood , Diet/veterinary , Digestion/drug effects , Dog Diseases/diet therapy , Dog Diseases/enzymology , Dogs , Female , Liver Diseases/enzymology , Male , MicroRNAsABSTRACT
BACKGROUND: Enlargement of the prostate is associated with prostatic diseases in dogs, and an estimation of prostatic size is a central part in the diagnostic workup. Ultrasonography is often the method of choice, but biomarkers constitute an alternative. Canine prostate specific esterase (CPSE) shares many characteristics with human prostate specific antigen (PSA) and is related to prostate size. In men with clinical symptoms of prostatic disease, PSA concentrations are related to prostate growth. The aims of the present follow-up study were to evaluate if the concentration of CPSE is associated with future growth of the prostate, and if analysis of a panel of 16 steroids gives further information on prostatic growth. Owners of dogs included in a previous study were 3 years later contacted for a follow-up study that included an interview and a clinical examination. The prostate was examined by ultrasonography. Serum concentrations of CPSE were measured, as was a panel of steroids. RESULTS: Of the 79 dogs included at baseline, owners of 77 dogs (97%) were reached for an interview, and 22 were available for a follow-up examination. Six of the 79 dogs had clinical signs of prostatic disease at baseline, and eight of the remaining 73 dogs (11%) developed clinical signs between baseline and follow-up, information was lacking for two dogs. Development of clinical signs was significantly more common in dogs with a relative prostate size of ≥2.5 at baseline (n = 20) than in dogs with smaller prostates (n = 51). Serum concentrations of CPSE at baseline were not associated with the change in prostatic size between baseline and follow-up. Serum concentrations of CPSE at baseline and at follow-up were positively associated with the relative prostatic size (Srel) at follow-up. Concentrations of corticosterone (P = 0.024), and the class corticosteroids (P = 0.0035) were positively associated with the difference in Srel between baseline and follow-up. CONCLUSIONS: The results support the use of CPSE for estimating present and future prostatic size in dogs ≥4 years, and the clinical usefulness of prostatic size for predicting development of clinical signs of prostatic disease in the dog. The association between corticosteroids and prostate growth warrants further investigation.
Subject(s)
Esterases/blood , Prostate/enzymology , Prostatic Hyperplasia/veterinary , Animals , Biomarkers/blood , Dog Diseases/diagnosis , Dog Diseases/enzymology , Dogs , Follow-Up Studies , Male , Prostate/diagnostic imaging , Prostatic Hyperplasia/diagnostic imaging , Prostatic Hyperplasia/enzymology , Steroids/blood , Ultrasonography/veterinaryABSTRACT
Ponatinib is a broad-spectrum tyrosine kinase inhibitor that targets numerous receptor tyrosine kinases (RTKs), including but not limited to fibroblast growth factor receptor (FGFR)-1, platelet derived growth factor receptor (PDGFR)-α, and vascular endothelial growth factor receptor (VEGFR)-2. This study evaluated the expression of FGFR-1, PDGFR-α, and VEGFR-2 in three canine mast cell tumor (MCT) cell lines (CM-MC1, VI-MC1, CoMS) and the effects of ponatinib on these MCT cell lines. Quantitative RT-PCR confirmed the expression of FGFR-1, PDGFR-α, and VEGFR-2 in the three MCT cell lines. Ponatinib exhibited dose- and time-dependent cytotoxicity in MCT cell lines via MTT assay. The IC50 for 24, 48, and 72 h across the three cell lines ranged from 38.47 nM to 103.3 nM, which is clinically comparable to dose ranges established for humans. Significantly increased apoptosis in each cell line was seen between 12 and 18 h after treatment with IC50 of ponatinib via Annexin-V and Caspase-3/7 assays. These data suggest that ponatinib could be a possible therapeutic agent for canine MCTs. Further studies are needed to investigate the prognostic value of FGFR-1, PDGFR-α, and VEGFR-2 in canine MCTs.
Subject(s)
Antineoplastic Agents/pharmacology , Dog Diseases/drug therapy , Imidazoles/pharmacology , Mast Cells/pathology , Pyridazines/pharmacology , Receptor Protein-Tyrosine Kinases/genetics , Skin Neoplasms/veterinary , Animals , Apoptosis/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Dog Diseases/enzymology , Dogs , Gene Expression , Receptor, Fibroblast Growth Factor, Type 1/genetics , Receptor, Platelet-Derived Growth Factor alpha/genetics , Skin Neoplasms/enzymology , Skin Neoplasms/pathology , Vascular Endothelial Growth Factor Receptor-2/geneticsABSTRACT
In the last years, the need to look for an accurate and precise diagnosis of prostatic diseases in dogs has grown. Among other diagnostic tools, the seric CPSE has been studied and identified as a valid and specific biomarker for prostatic disorders, since it can result significantly more elevated in dogs affected by several prostatic abnormalities, such as benign prostatic hyperplasia, bacterial prostatitis and prostatic carcinoma. Therefore, dosing CPSE in serum represents a new diagnostic and screening tool. Dosing CPSE in everyday clinical practice has three objectives: (a) the diagnosis of benign prostatic hyperplasia; (b) the preventive screening of prostatic disorders in healthy dogs; (c) the medical follow-up in subjects with prostatic disorders during and after medical therapy. Neither circadian rhythms nor transrectal palpation performed during the andrological examination do affect CPSE. A sexual rest of at least 24 hr before dosing CPSE is recommended as it is affected by ejaculation.
Subject(s)
Carcinoma/veterinary , Diagnostic Tests, Routine/veterinary , Dog Diseases/diagnosis , Esterases/metabolism , Genital Neoplasms, Male/veterinary , Prostatic Hyperplasia/veterinary , Prostatitis/veterinary , Andrology , Animals , Biomarkers , Carcinoma/diagnosis , Carcinoma/enzymology , Dog Diseases/enzymology , Dogs , Genital Neoplasms, Male/diagnosis , Genital Neoplasms, Male/enzymology , Male , Prostate/chemistry , Prostatic Hyperplasia/diagnosis , Prostatic Hyperplasia/enzymology , Prostatitis/diagnosis , Prostatitis/enzymologyABSTRACT
Ultrasonography is one of the most common methods for the diagnosis of prostate disorders, such as benign prostatic hyperplasia (BPH), in dogs. Changes in the echotexture are one of the indicators used to diagnose prostate disorders. The purpose of this study was to investigate the changes occurred in the dogs' prostate echotexture during the induction of BPH using image analysis. Twenty sexually mature male intact mixed-breed dogs were selected and divided randomly into control and BPH-induced groups. BPH was induced using testosterone and estrogen injections for 63 days. The ultrasound imaging of the dogs' prostate was performed during the induction of BPH on days 0, 21, 42, and 63. The echotexture of the prostate parenchyma was analyzed using the Image J software. Then, the changes in the echotexture and its correlation and linear regression with the prostate volume and canine prostate specific esterase (CPSE) concentration were evaluated by statistical tests. The prostate parenchyma echotexture did not show any significant changes during the induction of BPH and in comparison with that of the control group. While prostate volume and CPSE concentration increased significantly, indicating that BPH was induced in the dogs. There was no significant correlation and linear regression between the prostate echotexture and prostate volume or between the CPSE concentration and prostate echotexture. According to the results, the alteration in the prostate parenchymal echotexture did not occur in the early stages of induced BPH, but significant changes occurred in the prostate volume and CPSE concentration during those early stages.
Subject(s)
Dog Diseases/pathology , Esterases/blood , Prostate/enzymology , Prostatic Hyperplasia/diagnostic imaging , Ultrasonography/methods , Animals , Biomarkers/blood , Dog Diseases/enzymology , Dogs , Male , Organ Size , Prostatic Hyperplasia/pathology , Prostatic Hyperplasia/veterinary , Ultrasonography/veterinaryABSTRACT
Canine degenerative myelopathy (DM) is a fatal progressive neurodegenerative disease. Mutations in the superoxide dismutase 1 (SOD1) gene have been shown to be the major risk factor for DM, and it is hypothesized that neural degeneration is caused by a "gain of toxic function" of mutant SOD1. In this study, the spinal cord microRNA (miRNA) profiles of DM-affected dogs were investigated to elucidate the pathomechanisms of DM. Quantification of 277 miRNAs identified three up-regulated miRNAs and 18 down-regulated miRNAs in the spinal cords of DM-affected dogs. Based on gene ontology analysis, the target cluster of up-regulated miRNAs was associated with protein expression or modification and cellular response, and that of down-regulated miRNAs was associated with tissue development. In these clusters, we focused on the mechanism of protein ubiquitination. Polyubiquitination assay demonstrated that canine SOD1 proteins were polyubiquitinated and degraded by proteasomes. Immunohistochemistry of the spinal cords of DM-affected dogs showed that mutant SOD1 aggregations were not ubiquitin immunopositive. Using cultured cells, co-transfection of canine SOD1 and up-regulated miRNA in DM-affected dogs demonstrated that miR-23a, miR-142 and miR-221 significantly increased the proportion of cells with mutant SOD1 aggregation. These results suggested that up-regulated miRNAs in the spinal cords of DM-affected dogs may inhibit ubiquitination of misfolded SOD1 protein and induce mutant SOD1 aggregations, leading to further progression of degenerative processes in the DM pathology.
Subject(s)
Dog Diseases/metabolism , MicroRNAs/metabolism , Neurodegenerative Diseases/enzymology , Neurodegenerative Diseases/veterinary , Spinal Cord/metabolism , Superoxide Dismutase-1/metabolism , Animals , Cell Line , Dog Diseases/enzymology , Dog Diseases/genetics , Dogs , HEK293 Cells , Humans , Immunohistochemistry , Mutation , Neurodegenerative Diseases/genetics , Neurodegenerative Diseases/metabolism , Protein Folding , Spinal Cord/pathology , Superoxide Dismutase-1/genetics , Up-RegulationABSTRACT
OBJECTIVE: Postoperative cognitive dysfunction (POCD) may be related to brain injury. S100B protein and neuron-specific enolase (NSE) have been investigated as potential biochemical markers of neural cell injury in animals and humans. This study aimed to investigate the association between POCD, brain injury and serum concentrations of S100B and NSE after periodontal surgery in aged dogs. STUDY DESIGN: Prospective observational animal study. ANIMALS: A total of 24 male and female dogs undergoing periodontal surgery. METHODS: Dogs were separated into two groups based on age: control group, 10 dogs ≤ 8 years and aged group, 14 dogs > 8 years. Cognitive function was measured preoperatively and on the seventh postoperative day using the Canine Cognitive Dysfunction Rating scale and the Age-Related Cognitive and Affective Disorders scale. S100B protein and NSE serum concentrations were measured before and immediately after the surgery. RESULTS: POCD was not observed after surgery in the present study. Serum concentrations of S100B and NSE were increased postoperatively in the control group but not in the aged group (p = 0.04 and 0.03, respectively). Preoperative S100B serum concentrations were significantly higher in the aged group (p = 0.01). CONCLUSIONS: There was no association between POCD and high concentrations of S100B and NSE in dogs. However, increased postoperative serum concentrations of S100B and NSE were found in the control group after surgery, an effect that may indicate neural damage. CLINICAL RELEVANCE: The results suggest that anesthesia and oral surgery are associated with higher postoperative serum concentrations of S100B and NSE in dogs ≤ 8 years old, which may indicate neural damage. Serum concentrations of S100B were elevated in aged dogs before anesthesia, a finding that might be related to chronic preoperative brain damage.
Subject(s)
Anesthesia/veterinary , Dog Diseases/diagnosis , Phosphopyruvate Hydratase/blood , Postoperative Cognitive Complications/diagnosis , S100 Calcium Binding Protein beta Subunit/blood , Aging , Animals , Case-Control Studies , Dog Diseases/blood , Dog Diseases/enzymology , Dogs , Female , Male , Postoperative Cognitive Complications/bloodABSTRACT
Background: In several mammals, subfertility or infertility associated with endometritis was reported. Although there have been studies about endometritis in bitches, the pathophysiological mechanisms are not completely known. Aim: This study aimed to evaluate the immunohistochemical expression of Cyclooxygenase 2 (COX2) in clinically healthy bitches with normal uterine tissue and bitches with endometritis. Methods: Forty-eight mixed breed bitches in diestrus were used. Uterine biopsies were collected for diagnosis [normal endometrium (n = 15; NE), cystic endometrial hyperplasia (n = 1), atrophy (n= 2), acute endometritis (n = 9; AE), subacute endometritis (n = 7; SE), and chronic endometritis (n = 14; CE)]. Immunostaining and quantification of positively stained cells was performed on full-thickness uterine biopsies. Data were analyzed by the GLIMMIX procedure of SAS. Results: COX2 immunostaining was scattered and restricted to cells in the stroma in bitches with NE. However, in bitches with endometritis, strong staining was observed in the luminal epithelium, glandular epithelium, and stromal cells. Staining was also observed in inflammatory cells localized in the stroma as well as inside of the glands. The percentage of COX2 positive stromal cells in bitches with AE, SE, and CE was significantly higher compared with NE (p < 0.005). In addition, the percentage of COX2 positive stromal cells in bitches with SE, and CE was significantly lower compared with AE (p < 0.003). Conclusion: COX2 could be involved in the pathophysiological mechanisms producing endometritis without the presence of cystic endometrial hyperplasia in bitches. However, further researches on this topic are required.
Subject(s)
Cyclooxygenase 2/metabolism , Dog Diseases/enzymology , Endometrial Hyperplasia/veterinary , Endometritis/veterinary , Animals , Diestrus , Dog Diseases/physiopathology , Dogs , Endometrial Hyperplasia/enzymology , Endometrial Hyperplasia/physiopathology , Endometritis/enzymology , Endometritis/physiopathology , Female , Immunohistochemistry/veterinary , Stromal Cells/enzymology , Uterus/enzymology , Uterus/physiopathologyABSTRACT
BACKGROUND: Diagnosis of pancreatic diseases in dogs is still challenging because of variable clinical signs, which do not always correspond with clinical pathology and histopathological findings. OBJECTIVES: To characterize inflammatory and neoplastic pancreatic diseases of dogs and to correlate these findings with clinical findings and canine pancreatic lipase immunoreactivity (cPLI) results. ANIMALS: Tissue specimens and corresponding blood samples from 72 dogs submitted for routine diagnostic testing. METHODS: Four groups were defined histologically: (1) normal pancreas (n = 40), (2) mild pancreatitis (n = 8), (3) moderate or severe pancreatitis (acute, n = 11; chronic, n = 1), and (4) pancreatic neoplasms (n = 12). An in-house cPLI ELISA (<180 µg/L, normal; >310 µg/L, pancreatitis) was performed. RESULTS: In dogs with normal pancreas, 92.5% of serum cPLI results were within the reference range and significantly lower than in dogs with mild acute pancreatitis, moderate or severe acute pancreatitis and pancreatic tumors. In dogs with moderate or severe acute pancreatitis, cPLI sensitivity was 90.9% (95% confidence interval [CI], 58.7%-99.8%). Most dogs (9/12) with pancreatic tumors (group 4) had additional pancreatic inflammation and cPLI results were increased in 10 dogs. CONCLUSIONS AND CLINICAL IMPORTANCE: High cPLI indicates serious acute pancreatitis but underlying pancreatic neoplasms should also be taken into consideration. This study confirms the relevance of histopathology in the diagnostic evaluation of pancreatic diseases.
Subject(s)
Dog Diseases/diagnosis , Lipase/immunology , Pancreatic Neoplasms/veterinary , Pancreatitis/veterinary , Animals , Dog Diseases/enzymology , Dog Diseases/pathology , Dogs , Female , Lipase/blood , Male , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/enzymology , Pancreatitis/diagnosis , Pancreatitis/enzymologyABSTRACT
The monitoring of serum prostatic biomarkers during the treatment will help clinicians to know the statement of the response to finasteride in dogs affected by benign prostatic hyperplasia (BPH). The present study was aimed to assess changes in the serum canine prostate-specific esterase (CPSE), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), testosterone, dihydrotestosterone (DHT) and prostate volume evaluation using ultrasonographic examination during the treatment with finasteride in BPH-induced dogs. Twenty dogs were divided into 4 groups (nâ¯=â¯5): BPHâ¯+â¯finasteride group, dogs which were induced for BPH and received oral finasteride once daily for 1 month; BPH group, dogs which were induced for BPH and received placebo; finasteride group, normal dogs which received finasteride; and normal group, normal intact dogs which did not receive treatment. Blood sampling and ultrasonography examination were performed on days 0, 14, and 28. The administration of finasteride led to a significant decrease in the concentration of the prostate-specific biomarkers (PSA, CPSE), DHT, testosterone, and the volume of the prostate in BPHâ¯+â¯finasteride group compared with the BPH group during 1 month. Interestingly, the PAP concentration did not change in the BPH-induced dogs and in dogs treated with finasteride. It seems that the monitoring of serum PSA and CPSE levels and ultrasonographic examination of the prostate are useful methods for following up the response to finasteride treatment in dogs affected by BPH.
Subject(s)
Biomarkers/blood , Dog Diseases/drug therapy , Finasteride/pharmacology , Prostatic Hyperplasia/veterinary , 5-alpha Reductase Inhibitors , Acid Phosphatase/blood , Animals , Dihydrotestosterone/blood , Dog Diseases/blood , Dog Diseases/enzymology , Dogs , Esterases/blood , Estradiol/administration & dosage , Male , Prostate/diagnostic imaging , Prostate-Specific Antigen/blood , Prostatic Hyperplasia/blood , Prostatic Hyperplasia/drug therapy , Testosterone/administration & dosage , Testosterone/blood , Ultrasonography/veterinaryABSTRACT
Cutaneous squamous cell carcinoma (cSCC) is one of the most common types of malignant skin cancer in dogs, representing 3.9-10.4% of all canine skin tumours. Although the metastatic potential of cSCC is debated, it appears to mimic that observed in man. In man, predictive histopathological features for metastasis include tumour depth, lesions >5-6 mm in depth, and invasion of muscle, cartilage or bone. In dogs, some reports have focused on the clinical features and long-term progression of cSCC, but a gold standard treatment has not yet been developed. We explored the protein expression of kallikrein-related peptidase 5 (KLK5), an important modulator of skin homeostasis, in normal canine skin and in examples of cSCC. KLK5 was highly expressed in the upper stratum granulosum, stratum corneum, hair follicles and sweat glands, skin sites where human KLK5 has been shown to be involved in physiological processes including keratinocyte desquamation, antimicrobial defence, lipid permeability and pigmentation. In cSCC, tumour cells at the deep margin, as well as those in the centre of keratin pearls, displayed cytoplasmic expression of KLK5. Some of the KLK5 immunoreactive cells also expressed vimentin, suggesting that they may be undergoing epithelial-mesenchymal transition and therefore have a more invasive behaviour than those expressing only KLK5. KLK5 may be a novel molecular biomarker useful for predicting prognosis of cSSC in dogs.
Subject(s)
Carcinoma, Squamous Cell/veterinary , Dog Diseases/enzymology , Kallikreins/metabolism , Skin Neoplasms/veterinary , Animals , Carcinoma, Squamous Cell/pathology , Dog Diseases/pathology , Dogs , Epithelial-Mesenchymal Transition , Female , Male , Skin Neoplasms/pathologyABSTRACT
This study was designed to evaluate the antioxidative status of serum by measuring its total antioxidant capacity, as well as the antioxidant enzyme activity (superoxide dismutase, catalase, and glutathione reductase), in dogs with various stages of degenerative mitral valve disease (DMVD) compared to healthy controls. In total, 71 client-owned dogs in different stages of DMVD, which included healthy controls, took part in the study. Following an anamnesis, clinical examination, standard transthoracic echocardiograpic examination, chest X-ray, complete blood (cell) count, and serum biochemistry, dogs were divided into 2 study groups. Blood was drawn from each dog once at the time of presentation and selected antioxidant parameters were measured using commercially available assay kits. The activity of superoxide dismutase gradually decreased in the more advanced stages of DMVD, while the activity of catalase was significantly higher in the group of dogs with asymptomatic DMVD compared to healthy controls and dogs with symptomatic DMVD. No significant changes were noted in total antioxidant capacity and the activity of glutathione reductase. Results suggested that DMVD has a significant impact on the activity of superoxide dismutase and catalase in the serum of the tested dogs. Knowledge of changes in the activity of antioxidative enzymes may warrant further studies, possibly to evaluate the potential role of compounds with antioxidative properties in the clinical outcome of dogs with DMVD.
La présente étude a été conçue afin d'évaluer le statut antioxydant du sérum en mesurant sa capacité antioxydante totale, ainsi que l'activité antioxydante enzymatique (superoxyde dismutase, catalase, et glutathion réductase), chez des chiens avec des degrés divers de maladie dégénérative de la valvule mitrale (DMVD) comparativement à des témoins en santé. Au total, 71 chiens appartenant à des clients à différents stades de DMVD, qui incluaient des témoins en santé, ont pris part à cette étude. À la suite de la prise d'anamnèse, d'un examen clinique, d'un examen échocardiographie transthoracique standard, de radiographie thoracique, d'un comptage cellulaire sanguin complet, et d'analyse biochimique sérique, les chiens étaient séparés en deux groupes d'étude. Du sang fut prélevé de chaque chien une fois au moment de la présentation et les paramètres antioxydants sélectionnés furent mesurés à l'aide d'une trousse disponible commercialement. L'activité de la superoxyde dismutase diminuait graduellement dans les stades plus avancés de DMVD, alors que l'activité de la catalase était significativement plus élevée dans le groupe de chiens avec une DMVD asymptomatique comparativement aux témoins en santé et aux chiens avec une DMVD symptomatique. Aucun changement significatif n'était noté dans la capacité antioxydante totale et dans l'activité de la glutathion réductase. Les résultats suggèrent que la DMVD a un impact significatif sur l'activité de la superoxyde dismutase, et de la catalase dans le sérum des chiens testés. Des connaissances sur les changements dans l'activité des enzymes antioxydantes pourraient justifier des études additionnelles, possiblement pour évaluer le rôle potentiel de produits avec des propriétés antioxydantes dans le devenir clinique de chiens avec DMVD.(Traduit par Docteur Serge Messier).
Subject(s)
Antioxidants/metabolism , Catalase/blood , Dog Diseases/enzymology , Glutathione Reductase/blood , Mitral Valve Insufficiency/veterinary , Superoxide Dismutase/blood , Analysis of Variance , Animals , Blood Cell Count/veterinary , Blood Chemical Analysis/veterinary , Case-Control Studies , Dog Diseases/blood , Dog Diseases/diagnosis , Dogs , Echocardiography/veterinary , Female , Heart Failure/enzymology , Heart Failure/etiology , Heart Failure/veterinary , Male , Mitral Valve/diagnostic imaging , Mitral Valve/pathology , Mitral Valve Insufficiency/blood , Mitral Valve Insufficiency/diagnosis , Mitral Valve Insufficiency/enzymologyABSTRACT
Mammary gland tumors are a heterogeneous group of neoplastic diseases. Genetic studies make it possible to determine genetic profiles and identify new molecular markers. The aim of the study was to evaluate the gene expression profile of canine mammary carcinomas and identify potential prognostic markers. Twelve mammary cancer samples from bitches were collected for the evaluation of global gene expression. Microarray assays were performed using commercial kits. Statistical analysis of the microarray was done using moderate t-statistic and adjusted using the Benjamini and Hochberg procedure. Differential connectivity analysis was also performed. Enrichment analyses were conducted using WebGestalt. P-values were calculated using hypergeometric statistics and adjusted using the Benjamini and Hochberg procedure. The HYAL-1 gene was validated using quantitative PCR (qPCR). There were 878 upregulated genes and 821 downregulated genes in the neoplasms studied. Enrichment analysis (individual analysis) identified the HYAL-1 gene as a potential marker of tumorigenesis and tumor recurrence. Differential connectivity analysis demonstrated 262 differentially connected genes.
Subject(s)
Dog Diseases/genetics , Mammary Neoplasms, Animal/genetics , Animals , Biomarkers, Tumor/metabolism , DNA, Neoplasm , Dog Diseases/enzymology , Dogs , Female , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Hyaluronoglucosaminidase/genetics , Hyaluronoglucosaminidase/metabolism , Mammary Neoplasms, Animal/enzymology , Oligonucleotide Array Sequence Analysis , Real-Time Polymerase Chain Reaction/veterinaryABSTRACT
BACKGROUND: Serum canine pancreatic lipase immunoreactivity (cPLI) concentrations have become the standard laboratory test used to diagnose canine pancreatitis. Recently, a new point-of-care assay for cPLI, the VetScan cPL rapid test (VetScan cPL), has become available, but analytical validation data have not yet been published. OBJECTIVE: This study aimed to perform a partial analytical validation of the VetScan cPL. METHODS: Leftover serum samples from a diagnostic laboratory were used. Adherence to the manufacturer's guidelines, linearity, repeatability, and reproducibility were evaluated. Results of the VetScan cPL were correlated with the Spec cPL results. RESULTS: Observed-to-expected ratios for dilutional parallelism ranged from 77.4% to 162.9% (mean 119.3%). Intra-assay and inter-assay variabilities ranged from 16.9% to 36.7% (mean 25.1%) and from 14.1% to 51.2% (mean 31.8%), respectively. Adherence to the manufacturer's specification regarding results within ± 60 µg/L of the Spec cPL result was only achieved for 39% of the measurements. The VetScan cPL and Spec cPL correlation showed a Spearman's r of .758 for 29 data pairs. CONCLUSIONS: Under the conditions of this study, the VetScan cPL did not adhere to the manufacturer's specifications for most measurements. Also, the VetScan cPL showed suboptimal linearity and was not precise. In conclusion, the VetScan cPL failed basic analytical validation.
Subject(s)
Dog Diseases/enzymology , Immunoenzyme Techniques/veterinary , Lipase/blood , Pancreatitis/veterinary , Animals , Dog Diseases/blood , Dogs , Hyperlipidemias/blood , Hyperlipidemias/enzymology , Hyperlipidemias/veterinary , Pancreatitis/blood , Pancreatitis/enzymology , Point-of-Care Testing , Reproducibility of ResultsABSTRACT
OBJECTIVE: In the literature, the BRAF mutation is reported to have been identified in 80 % of the examined canine prostate carcinomas (PCa). The objectives of this study were to test for the BRAF mutation in canine PCa in our cohort of canine patients, to determine the specificity and sensitivity of the test for this mutation, as well as to identify the association between the presence of the BRAF mutation and the histologic picture of PCa. Moreover, the method was to be established in cytology samples. MATERIAL AND METHODS: Biopsy samples (n = 70) and cytologic slides (n = 17) of 87 dogs with prostatic diseases were selected. Prostatic diseases were classified according to the literature as benign prostate hyperplasia (BPH, n = 22), prostatitis (n = 14), squamous cell metaplasia of the prostate (PM, n = 2), atrophy following castration (n = 3) und PCa (n = 46; histologic diagnosis n = 35, cytologic diagnosis n = 11). Additionally, the Gleason score was determined for each PCa. DNA isolation was performed using commercially available kits. Exon 15 was examined using the TaqMan® SNP assay. The specificity and sensitivity of the test were calculated. RESULTS: A Gleason score of 6 and 7 was shown in 1 PCa each, in 33 cases the score ranged between 8 and 10. Sufficient amount of good-quality DNA was isolated from all samples. 28/46 PCa were tested positive for the BRAF mutation (sensitivity 61 %). The BRAF mutation was not evident in any of the dogs with BPH, prostatitis, PM or atrophy (specificity 100 %). PCa positive for the BRAF mutation exhibited a significantly higher Gleason score (p = 0.002) in comparison to PCa without this mutation. CONCLUSION AND CLINICAL RELEVANCE: BRAF mutation analysis is a highly specific method and may aid in confirming the diagnosis of PCa in histologically and cytologically questionable cases. PCa positive for BRAF mutation exhibited more criteria of malignancy than PCa without this mutation. The clinical, therapeutic, and prognostic relevance of these findings needs to be evaluated by further studies.
Subject(s)
Dog Diseases/genetics , Mutation , Prostatic Diseases/veterinary , Proto-Oncogene Proteins B-raf/genetics , Animals , Dog Diseases/diagnosis , Dog Diseases/enzymology , Dog Diseases/pathology , Dogs , Genetic Markers/genetics , Male , Prostatic Diseases/diagnosis , Prostatic Diseases/genetics , Prostatic Diseases/pathologyABSTRACT
Chronic mitral valve disease (CMVD) is the most common cardiovascular disease in dogs, causing decreased cardiac output that results in poor tissue perfusion and tissue damage to kidneys, pancreas, and other organs. The purpose of this study was to evaluate the relationships between heart disease severity and N-terminal pro B-type natriuretic peptide (NT-proBNP) and lipase in dogs with CMVD, as well as to evaluate longitudinal changes in these values. A total of 84 dogs participated in this 2015 to 2017 study. Serum values of NT-proBNP and lipase were analyzed; radiography was used to measure the vertebral heart score and assess various echocardiographic values. NT-proBNP showed a strong positive correlation with increasing stage of heart disease; lipase showed a mild positive correlation with heart disease stage. When the three values (NT-proBNP, lipase and month) were continuously measured at 6-month intervals, all showed a correlation with the increasing length of the disease.
Subject(s)
Dog Diseases/physiopathology , Lipase/blood , Mitral Valve Insufficiency/veterinary , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Animals , Chronic Disease , Dog Diseases/enzymology , Dog Diseases/metabolism , Dogs , Echocardiography , Longitudinal Studies , Mitral Valve Insufficiency/enzymology , Mitral Valve Insufficiency/metabolism , Mitral Valve Insufficiency/physiopathology , Republic of KoreaABSTRACT
Hereditary ß-mannosidosis causing progressive lysosomal neuropathy and other clinical signs, has been previously described in humans, Nubian goats, and Salers cattle. Here we report the clinicopathological, metabolic, and molecular genetic features of canine beta-mannosidase (MANBA, EC 3.2.1.25) deficiency. A 1-year-old male mix-breed dog from St. Kitts was presented with progressive stumbling, weakness, and regurgitation. Vacuolated lymphocytes were observed on the blood film. Postmortem findings included marked enlargement of nerves, megaesophagus, and internal hydrocephalus. Vacuolated macrophages, neurons, and secretory epithelial cells suggested an oligosaccharide storage disease. Plasma concentration of the ß-mannosidosis specific oligosaccharide was approximately 75 fold that of controls. The plasma beta-mannosidase activity was severely reduced to ~5% of controls; five other lysosomal acid hydrolase activities were increased or within their normal reference interval. Genomic sequencing of this dog's MANBA gene identified a homozygous exonic five bp tandem duplication in the penultimate exon of the MANBA gene (c.2377_2381dupTATCA) which results in a reading frame shift, altering the subsequent amino acid sequence and creating a premature stop codon. The truncated beta-mannosidase enzyme is expected to be dysfunctional. This enzyme deficiency causes the accumulation of un-degraded oligosaccharides in cells, which affect the myelination of the peripheral and central nervous systems. This insertion was not encountered in 121 and 80-screened samples from dogs on St. Kitts (all were homozygous for wild-type) and Philadelphia region (wild-type), respectively. In conclusion, canine ß-mannosidosis has similar clinicopathological features with some human patients, but milder signs than in ruminants and more severe than in knockout mice. Hence, dogs with ß-mannosidosis could become a valuable disease model for the human disease.